Metacognitive Therapy for Individuals at High Risk of Developing Psychosis: A Pilot Study
- PMID: 32010004
- PMCID: PMC6978773
- DOI: 10.3389/fpsyg.2019.02741
Metacognitive Therapy for Individuals at High Risk of Developing Psychosis: A Pilot Study
Abstract
Developing effective interventions for preventing first episode psychosis have been an important research focus in the last decade. Cognitive behavioral therapy is a currently indicated treatment for people at ultra-high risk of psychosis, however, access and resource issues limit its delivery within the NHS. Treatments which partial out potential active ingredients and are aimed at a range of psychological difficulties seen within this population have the potential to be more efficacious and efficient. We conducted a single-arm exploratory pilot trial, designed to investigate the feasibility and acceptability of Metacognitive therapy for individuals at ultra-high risk (UHR) of developing psychosis. Trial uptake was good, with 11 out of 12 referred individuals meeting for an eligibility assessment (one individual was excluded prior to the assessment). Of these, 10 individuals were eligible and included in the trial. Retention to treatment was high with 80% treatment adherence gained and an overall average of 8 sessions completed. All participants were offered follow-up assessments immediately post-treatment and at 6 months, which comprised measures of psychotic like experiences, anxiety and depression, and metacognitive processes implicated in the model. Retention to the post-treatment (12-week) follow-up was good, with 80% completion; however retention to the 6-month follow-up was lower at 60%. Clinically significant results were observed in psychotic like experiences, anxiety, depression and functioning with medium to large effect sizes. Measures related to beliefs and processes targeted within MCT showed clinically significant change with medium to large effect sizes. Our results suggest that MCT based upon a specific metacognitive model for individuals meeting ARMS criteria may be an important treatment target and warrants further attention. Limitations and possible focuses for future research are discussed. Registration: ISRCTN53190465 http://www.isrctn.com/ISRCTN53190465.
Keywords: at risk mental states; cognitive attentional syndrome; metacognition; metacognitive therapy; psychosis.
Copyright © 2020 Parker, Mulligan, Milner, Bowe and Palmier-Claus.
Figures
Similar articles
-
A targeted psychological treatment for sleep problems in young people at ultra-high risk of psychosis in England (SleepWell): a parallel group, single-blind, randomised controlled feasibility trial.Lancet Psychiatry. 2023 Sep;10(9):706-718. doi: 10.1016/S2215-0366(23)00203-1. Epub 2023 Aug 7. Lancet Psychiatry. 2023. PMID: 37562423 Clinical Trial.
-
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217. Cochrane Database Syst Rev. 2022. PMID: 36321557 Free PMC article.
-
Improving the Effectiveness of Psychological Interventions for Depression and Anxiety in Cardiac Rehabilitation: PATHWAY-A Single-Blind, Parallel, Randomized, Controlled Trial of Group Metacognitive Therapy.Circulation. 2021 Jul 6;144(1):23-33. doi: 10.1161/CIRCULATIONAHA.120.052428. Epub 2021 Jun 21. Circulation. 2021. PMID: 34148379 Free PMC article. Clinical Trial.
-
Metacognitive beliefs in the at-risk mental state: A systematic review and meta-analysis.Behav Res Ther. 2017 Mar;90:25-31. doi: 10.1016/j.brat.2016.12.004. Epub 2016 Dec 8. Behav Res Ther. 2017. PMID: 27960094 Review.
-
Psychosocial Approaches in the Treatment of Psychosis: Cognitive Behavior Therapy for Psychosis (CBTp) and Metacognitive Training (MCT).Clin Schizophr Relat Psychoses. 2017 Fall;11(3):156-163. doi: 10.3371/CSRP.MEBA.022015. Epub 2015 Feb 24. Clin Schizophr Relat Psychoses. 2017. PMID: 25711506 Review.
Cited by
-
The Scope of Metacognitive Therapy in the Treatment of Psychiatric Disorders.Cureus. 2022 Mar 23;14(3):e23424. doi: 10.7759/cureus.23424. eCollection 2022 Mar. Cureus. 2022. PMID: 35475111 Free PMC article. Review.
-
A positive mental imagery intervention for targeting suicidal ideation in university students: A pilot study.Clin Psychol Psychother. 2022 Jul;29(4):1392-1402. doi: 10.1002/cpp.2720. Epub 2022 Feb 13. Clin Psychol Psychother. 2022. PMID: 35122355 Free PMC article.
-
Feasibility and outcome of metacognitive therapy for major depressive disorder: a pilot study.BMC Psychiatry. 2020 Nov 26;20(1):566. doi: 10.1186/s12888-020-02976-4. BMC Psychiatry. 2020. PMID: 33243217 Free PMC article.
References
-
- Amminger G. P., Schäfer M. R., Papageorgiou K., Klier C. M., Cotton S. M., Harrigan S. M., et al. (2010). Long-chain ω-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch. Gen. Psychiatry 67 146–154. - PubMed
-
- Bjelland I., Dahl A. A., Haug T. T., Neckelmann D. (2002). The validity of the hospital anxiety and depression scale: an updated literature review. J. Psychosom. Res. 52 69–77. - PubMed
LinkOut - more resources
Full Text Sources